补体C4在新诊断多发性骨髓瘤患者中的预后价值  

The value of completement C4 in newly diagnosed multiple myeloma

作　　者：冷晴 刘伟[1] 管俊 LENG Qing;LIU Wei;GUAN Jun(Yangzhou University Medical College,Y angzhou,225000,China;Department of Hematolo-gy,Northern Jiangsu People's Hospital)

机构地区：[1]扬州大学医学院,江苏扬州225000 [2]苏北人民医院血液科

出　　处：《临床血液学杂志》2023年第3期175-180,共6页Journal of Clinical Hematology

摘　　要：目的:探讨补体C4对新诊断多发性骨髓瘤(MM)患者生存预后的价值。方法:回顾性分析2015年1月—2020年6月在江苏省苏北人民医院确诊的111例MM患者的临床资料,通过Cox回归分析对其生存预后进行单因素及多因素分析,通过logistic回归分析对2年生存期进行单因素及多因素分析。结果:111例MM患者中男59例,女52例,中位年龄64(34~86)岁,总体中位生存期为51个月。通过Cox回归分析进行生存预后分析,结果显示补体C4水平及年龄为影响预后的独立因素(P<0.05)。通过logistic回归分析对2年生存期进行分析,结果显示补体C4≥0.2 mg/mL、年龄≥70岁及白细胞计数≤4.4×109/L为独立预后因素,同时存在3个危险因素的患者2年内死亡的风险是存在0~2个危险因素患者的8倍(P<0.05)。结论:高补体C4水平的患者生存预后差,补体C4水平可以作为MM患者生存预后的潜在生物学标记物。Objective:To explore the predictive value of completement C4 in newly diagnosed multiple myeloma(MM).Methods:The clinical data of 111 newly diagnosed MM were retrospectively analyzed.The univariate and multivariate analysis for overall survival(OS)were made through Cox regression analysis and univariate and multivariate analysis for two-year survival were made through logistic regression analysis.Results:Among the 111 patients,there were 59 males and 52 females,with a medium age of 64(34-86)years and the medium OS was 51 months.It revealed that high C4 level and advanced age were the independent factors of OS through Cox regression analysis(P<0.05).C4≥0.2 mg/mL,age≥70 years and WBC≤4.4×10~9/L were independent factors for two-year survival through logistic regression analysis(P<0.05).It indicated that patients with 3 risk factors had 8 folds of mortality risk in two years than patients with 0-2 risk factors(P<0.05).Conclusion:Patients with high level C4 have poor OS and C4 can be the potential biomarker for OS of newly diagnosed MM.

关 键 词：多发性骨髓瘤 补体C4 生存分析 

分 类 号：R733.3[医药卫生—肿瘤]